Vascular PAR-1: activity and antagonism.
作者： Ninian N. Lang , Ingibjörg J. Guðmundsdóttir , David E. Newby
DOI: 10.1111/J.1755-5922.2010.00140.X
关键词:
摘要: Despite major advances in antiplatelet therapies, recurrent cardiovascular events remain high after acute coronary syndrome. Furthermore, incremental benefits achieved the reduction of atherothrombotic have almost always been at expense hemorrhagic side effects. Thrombin is most potent platelet activating factor known and it makes important interactions with endothelium vascular smooth muscle proinflammatory, proatherogenic Distinct from its activity within coagulation cascade, thrombin mediates these effects via protease-activated receptor type 1 (PAR-1) man. This review discusses role PAR-1 vasculature development novel antagonists. These drugs may provide antiatherothrombotic without attendant bleeding complications could represent a breakthrough for treatment diseases.
ed.ac.uk
sci-hub.se 参考文章(73)
R.M. Scarborough, M.A. Naughton, W Teng, D.T. Hung, J Rose, T.K. Vu, V.I. Wheaton, C.W. Turck, S.R. Coughlin, Tethered ligand agonist peptides. Structural requirements for thrombin receptor activation reveal mechanism of proteolytic unmasking of agonist function. Journal of Biological Chemistry. ,vol. 267, pp. 13146- 13149 ,(1992) , 10.1016/S0021-9258(18)42184-9
L.F. Brass, R R Vassallo, E Belmonte, M Ahuja, K Cichowski, J.A. Hoxie, Structure and function of the human platelet thrombin receptor. Studies using monoclonal antibodies directed against a defined domain within the receptor N terminus. Journal of Biological Chemistry. ,vol. 267, pp. 13795- 13798 ,(1992) , 10.1016/S0021-9258(19)49635-X
Randomized Trial of Aspirin, Sibrafiban, or Both for Secondary Prevention After Acute Coronary Syndromes Circulation. ,vol. 103, pp. 1727- 1733 ,(2001) , 10.1161/01.CIR.103.13.1727
Wolfgang Koenig, None, Fibrin(ogen) in cardiovascular disease: an update Thrombosis and Haemostasis. ,vol. 89, pp. 601- 609 ,(2003) , 10.1055/S-0037-1613566
Shaun R. Coughlin, Thrombin signalling and protease-activated receptors Nature. ,vol. 407, pp. 258- 264 ,(2000) , 10.1038/35025229
VALERIA S. OSSOVSKAYA, NIGEL W. BUNNETT, Protease-Activated Receptors: Contribution to Physiology and Disease Physiological Reviews. ,vol. 84, pp. 579- 621 ,(2004) , 10.1152/PHYSREV.00028.2003
Atsufumi Kawabata, Satoko Kubo, Yumiko Nakaya, Tsuyoshi Ishiki, Ryotaro Kuroda, Fumiko Sekiguchi, Naoyuki Kawao, Hiroyuki Nishikawa, Distinct roles for protease-activated receptors 1 and 2 in vasomotor modulation in rat superior mesenteric artery Cardiovascular Research. ,vol. 61, pp. 683- 692 ,(2004) , 10.1016/J.CARDIORES.2003.11.030
Bruce P. Damiano, Claudia K. Derian, Bruce E. Maryanoff, Han-Cheng Zhang, Patricia Andrade Gordon, RWJ‐58259: A Selective Antagonist of Protease Activated Receptor‐1 Cardiovascular Drug Reviews. ,vol. 21, pp. 313- 326 ,(2006) , 10.1111/J.1527-3466.2003.TB00124.X
Madhu Chintala, Kenji Shimizu, Masami Ogawa, Hiroya Yamaguchi, Masaki Doi, Peder Jensen, Basic and translational research on proteinase-activated receptors: antagonism of the proteinase-activated receptor 1 for thrombin, a novel approach to antiplatelet therapy for atherothrombotic disease. Journal of Pharmacological Sciences. ,vol. 108, pp. 433- 438 ,(2008) , 10.1254/JPHS.08R06FM
Junor A. Barnes, Shamjeet Singh, Aldrin V. Gomes, Protease activated receptors in cardiovascular function and disease Molecular and Cellular Biochemistry. ,vol. 263, pp. 227- 239 ,(2004) , 10.1023/B:MCBI.0000041864.14092.5B